Anti-diabetic drug refers to the medications consumed orally that are prescribed to treat diabetes mellitus (type 2). It treats diabetes (type 2) by lowering down the blood sugar level. These are also known as oral hypoglycemic agents or oral antihyperglycemic agents. Oral anti-diabetic drugs are often prescribed as monotherapy but in severe cases, can be given in combination with insulin.

The global Oral Anti-Diabetic Drug market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Oral Anti-Diabetic Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Oral Anti-Diabetic Drug market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
Takeda
Pfizer
Eli Lilly
Janssen Pharmaceuticals
Astellas
Boehringer Ingelheim
Merck And Co.
AstraZeneca
Bristol Myers Squibb
Novartis
Sanofi
Abbott
Biocon

Segment by Regions
North America
Europe
China
Japan

Segment by Type
Glimepiride
Gliclazide
Glyburide
Others

Segment by Application
Hospital
Research Institual